K9-ACV: A Customized Cancer Vaccines for Dogs
A Personalized Approach to Canine Cancer
K9-ACV stands for Canine Autologous Cancer Vaccine. Using the therapeutic approach of immunotherapy, our scientists have developed a cancer vaccine, created personally for your pet that can be incorporated in your pet’s cancer treatment plan. Our hope is that K9-ACV will improve and extend the quality of life for your dog. K9-ACV is designed for all operable canine tumors.
Cancer cells can be recognized as foreign by the immune system if those cancer cells are presented to the immune system in a manner that “breaks immune tolerance.” Decades of research in mouse and human models have shown that tumor cells are very much like normal cells in that they express self-antigens that the body is taught to ignore early in development and throughout life. An immunosuppressive environment produced by growing tumors promotes an immune response toward the tumor that is ineffective, allowing the tumor to grow unchecked.
What is the administration protocol?The injection protocol involves three administrations of a killed tumor vaccine. Each dose is administered on a monthly basis as shown in the schedule provided. We ask that the entire 1 ml volume of each vaccine dose be administered intradermally, although some leakage into subcutaneous tissue is expected. The vaccine will appear cloudy, which is not a problem. The vaccine consists of cellular fragments obtained from 10 million cells from the tumor, which accounts for the cloudy nature of the vaccine. All vaccines are rigidly tested for sterility and are not released to your practice unless sterility criteria are met.
What side effects should the owner be made aware of?
Safety and efficacy have not yet been established for use in canine patients. In similar human tumor vaccine studies, hundreds of vaccines have been administered on an out-patient basis. Following vaccination, patients are normally observed for roughly 1 hr. for any adverse event which in the experience of the investigators has been minor. Minor fever and minimal inflammation may occur over the next 48 hours. This inflammatory response is beneficial for the success of the vaccine.
Experimental Autologous Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been established.